SCHEMBL30838314

SCHEMBL30838314

Cn1cnnc1C1(c2ccc(F)c(NC(=O)c3cc(CNCC(C)(C)CF)cn(CC(F)(F)F)c3=O)c2)CC2(CC(C)(C)C2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30838379 0.97 CBL (0.31) —
SCHEMBL30838346 0.93 CBLB (0.35) —
SCHEMBL30838333 0.91 CBL (0.31) —
SCHEMBL30838239 0.91 CBL (0.31) —
SCHEMBL30838277 0.91 PDCD1 (0.32) —
SCHEMBL30838309 0.90 CBLB (0.32) —
SCHEMBL30838183 0.90 CBLB (0.31) —
SCHEMBL30838199 0.90 CBLB (0.39) —
SCHEMBL30838205 0.89 — —
SCHEMBL30838338 0.89 PDCD1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573085-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS Glenmark Pharmaceuticals Limited (IN) 2025-06-25 — — EP claimed
WO-2024038378-A1 SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2024-02-22 — — WO claimed
Send feedback